Patient group
Kinder, Jugendliche und Erwachsene mit primärer Hyperoxalurie Typ 1 (PH1)
completed2021-01-01D series
Lumasiran
Hyperoxalurie
Open official case page ↗
- Brand
- Oxlumo
- Manufacturer
- Alnylam Germany GmbH
G-BA action
final resolution
2021-07-01
Arzneimittel-Richtlinie/Anlage XII: Lumasiran (Hyperoxalurie)
Evidence-checked summary
The G-BA found a hint of non-quantifiable added benefit for Kinder, Jugendliche und Erwachsene mit primärer Hyperoxalurie Typ 1 (PH1). The G-BA issued a final resolution on 2021-07-01. The official page states that it took effect as follows: 01.07.2021. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2021-05-10
93 parsed turns
Oral hearing: Lumasiran (Hyperoxalurie)
Official Wortprotokoll · 15 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
Distinct actions and documents
2021-07-01
final resolution
Arzneimittel-Richtlinie/Anlage XII: Lumasiran (Hyperoxalurie)
The G-BA found a hint of non-quantifiable added benefit for Kinder, Jugendliche und Erwachsene mit primärer Hyperoxalurie Typ 1 (PH1). The G-BA issued a final resolution on 2021-07-01. The official page states that it took effect as follows: 01.07.2021. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗gba assessment amendmentAmendment zur Nutzenbewertung des G-BAOpen ↗iqwig cost assessmentBewertung der Therapiekosten und Patientenzahlen IQWiGOpen ↗annex xii current versionLumasiranOpen ↗gba assessmentNutzenbewertung G-BAOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗
Generic graph relations · 6
HAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII: Lumasiran (Hyperoxalurie)HAS HEARINGOral hearing: Lumasiran (Hyperoxalurie)OWNS DOCUMENTAmendment zur Nutzenbewertung des G-BAOWNS DOCUMENTBewertung der Therapiekosten und Patientenzahlen IQWiGOWNS DOCUMENTLumasiranOWNS DOCUMENTNutzenbewertung G-BA